California-based clinical-stage biopharmaceutical company Kyverna Therapeutics, Inc. (Nasdaq: KYTX) announced on Monday that it has named Warner Biddle as its new chief executive officer (CEO) and member of its board of directors, succeeding Peter Maag, Ph.D., effective immediately.

Biddle brings over 30 years of global pharmaceutical leadership, most recently serving as senior vice president, global head of Commercial at Kite Pharma. At Kite, he oversaw key product launches and market growth for Yescarta and Tecartus, solidifying the company's position in cell therapy. In 2023, Biddle also served as interim head of Kite, managing key operational functions.

Previously, Biddle held leadership roles at Genentech, Novartis and GlaxoSmithKline working in Canada, the United Kingdom and Switzerland.